ArticleMinerva endocrinologica2011
Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s).
Article in Minerva endocrinologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03693560 (The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Correlations of SELE genetic polymorphisms with risk of coronary heart disease and myocardial infarction: a meta-analysis.Molecular biology reports · 2014Pooled it
- Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.Cardiovascular diabetology · 2012 · on this mapTrial
- In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation.Journal, genetic engineering & biotechnology · 2024Article
- An update on chronic complications of diabetes mellitus: from molecular mechanisms to therapeutic strategies with a focus on metabolic memory.Molecular medicine (Cambridge, Mass.) · 2024Review
- Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications.The Journal of international medical research · 2020Article
- Relationship of adiponectin to markers of oxidative stress in type 2 diabetic patients: influence of incipient diabetes-associated kidney disease.International urology and nephrology · 2015Article
- Relationships of serum soluble E-selectin concentration with insulin sensitivity and metabolic flexibility in lean and obese women.Endocrine · 2014Article
- Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability.PloS one · 2014Article
- Type 2 diabetes and cardiovascular diseases: do they share a common soil? The Asian Indian experience.Heart Asia · 2012Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimAdipose tissue is now regarded as a source of proinflammatory mediators which may contribute to vascular injury, insulin resistance (IR), and atherogenesis, however, some of them have a protective role against vascular inflammation and/or IR; namely adiponectin and nitric oxide (NO). Adiponectin is a fat derived hormone, which enhances insulin sensitivity. In experimental studies adiponectin was shown to have anti-atherogenic properties by suppressing endothelial expression of adhesion molecules as endothelial-selectin (E-selectin) and inflammatory cytokines as high-sensitivity C-reactive protein (hsCRP), interleukin-1β (IL-1β), and monocyte chemotactic protein-1 (MCP-1). Therefore, the aim of the study was to evaluate plasma adiponectin, E-selectin, hsCRP, IL-1β, and MCP-1 concentrations in obese patients with and without coronary heart disease (CHD) having type 2 diabetes mellitus (DM) and evaluation of their relationship with selected anthropometric, biochemical, and clinical parameters.
methodsThe study group consisted of (N.=70) males, 20 of which served as healthy non-obese controls (group I) (mean age 38.5±3.7 years; mean BMI 28±1.2 kg/m2). Patients enrolled in the study were classified into the following groups: type 2 DM obese subjects without CHD (group II) (N.=25) (mean age 42.2±3 years; mean BMI 32.1±1.4 kg/m2) and type 2 DM obese subjects with CHD (group III) (N.=25) (mean age 40.6±3 years; mean BMI 31.5±1.2 kg/m2). Glucose and insulin estimation was performed and insulin resistance index (HOMA-IR) was calculated. In the fasting state, the plasma HbA1c, adiponectin, E-selectin, in comparison to hsCRP, IL-1β, MCP-1, and lipid parameters were estimated.
resultsFBG, HbA 1c %, lipids, insulin, MDA, NO, hsCRP, IL-?, MCP-1, Adiponectin as well as E-selectin concentration were significantly different in patients with type 2 DM and CHD in comparison to patients without CHD and moreover, the healthy control group (P=0.01). There was a significant negative correlation between adiponectin and E-selectin (r=-0.642; P=0.0001).
conclusionOur study supports the hypothesis that decreased level of adipokine(s), together with increased oxidative stress, pro-inflammatory marker(s) as well as endothelial adhesion molecule(s) contributes to the complex process of atherosclerosis in type 2 diabetic obese patients that may lead eventually to CHD.
Indexed as
Identifiers
22019747W1457270803What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.